Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q2 FY21 results · Jul–Sep 2020
Glenmark Pharmaceuticals reported revenue from operations of ₹2,952.48 crore (up 4.9% from Q2 FY20) and net profit of ₹233.99 crore (down 8.4% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,952.48 | 2,815.04 | +4.9% | 2,344.79 | +25.9% |
| Other income | (31.88) | 80.83 | Turned loss | 58.51 | Turned loss |
| Total income | 2,920.60 | 2,895.86 | +0.9% | 2,403.30 | +21.5% |
| Profit before tax | 339.38 | 347.30 | −2.3% | 357.61 | −5.1% |
| Net profit for the period | 233.99 | 255.54 | −8.4% | 254.04 | −7.9% |
| EPS, basic (₹) | 8.29 | 9.06 | not comparable | 9.00 | −7.9% |
| Net margin (%) | 7.9 | 9.1 | 10.8 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,062.16 | 1,789.82 | +15.2% | 1,682.92 | +22.5% |
| Other income | 63.40 | 192.47 | −67.1% | 134.85 | −53.0% |
| Total income | 2,125.57 | 1,982.29 | +7.2% | 1,817.77 | +16.9% |
| Profit before tax | 461.55 | 474.51 | −2.7% | 575.84 | −19.8% |
| Net profit for the period | 402.88 | 431.99 | −6.7% | 462.48 | −12.9% |
| EPS, basic (₹) | 14.28 | 15.31 | not comparable | 16.39 | −12.9% |
| Net margin (%) | 19.5 | 24.1 | 27.5 |
Consolidated
- Filed with BSE
- 09 Nov 2020, 09:45 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2020, 09:45 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE